Evidence map›Paper›PMID 26391682›Full record

ArticleGlycoconjugate journal2015

Serglycin protects against high fat diet-induced increase in serum LDL in mice.

Astri J Meen, Christian A Drevon, Gunnar Pejler, Trond G Jenssen, Ole Kristoffer Olstad, Magnus Åbrink, Svein O Kolset

Abstract read
PubMed Publisher
In one paragraph

Article in Glycoconjugate journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Astri J MeenDepartment of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Pb. 1046, Blindern, 0317, Oslo, Norway. a.j.meen@medisin.uio.no.
Christian A DrevonDepartment of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Pb. 1046, Blindern, 0317, Oslo, Norway.
Gunnar PejlerDepartment of Anatomy, Physiology, and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Trond G JenssenDepartment of Transplant Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Ole Kristoffer OlstadDepartment of Medical Biochemistry, Oslo University Hospital and University of Oslo, Oslo, Norway.
Magnus ÅbrinkDepartment of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Svein O KolsetDepartment of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Pb. 1046, Blindern, 0317, Oslo, Norway.
University of Oslo · NOSwedish University of Agricultural Sciences · SEUiT The Arctic University of Norway · NOUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteoglycans have been implicated in regulation of lipoprotein metabolism. However, the impact of serglycin, the major proteoglycan expressed by many hematopoietic- and endothelial cells, on lipoprotein metabolism has not been explored. Here we addressed this issue by comparing several parameters of lipid metabolism in wild type (WT) and serglycin-/- mice, both at baseline and after feeding mice the Paigen diet. We show that, after feeding this diet for 20 weeks, serglycin deficient mice exhibited elevated concentrations of serum LDL in comparison with WT mice, thus suggesting that serglycin protects against an elevation of serum LDL levels after intake of a high-fat diet. Body weight increased in both groups, but only significantly in the serglycin-/- group. To explore the mechanism underlying this phenotype, genome-wide expression analysis was performed on liver tissues from WT and serglycin-/- mice. This analysis showed that serglycin-deficiency is associated with differential expression of numerous genes involved in the regulation of lipid metabolism, suggesting that the impact of serglycin on LDL levels may be related to effects at the gene expression level. In particular, several members of the CYP gene family were differently regulated in serglycin-/- compared with WT mice. Moreover, upstream regulator analysis suggested that several pro-inflammatory pathways, including the NFκB pathway, could contribute to the impact of serglycin on LDL. Hence, the elevation of serum LDL seen in serglycin-/- mice may be linked to dysregulated inflammatory responses. Taken together, our findings introduce serglycin as a novel player in processes that regulate lipid metabolism.

Indexed as

Lipid MetabolismAnimalsDiet, High-FatFemaleLipoproteins, LDLMaleMiceMice, Inbred C57BLProteoglycansVesicular Transport ProteinsLipoproteins, LDLProteoglycansserglycinVesicular Transport ProteinsAtherosclerosisInflammationLDLPaigen dietProteoglycanSerglycin

Identifiers

PMID26391682
OpenAlexW1721017224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.